Noyola-Villalobos HF, Espinoza-Mercado F, Jiménez-Chavarría E, Loera-Torres MA, Rivera-Navarrete E

Language: Spanish
References: 8
Page: 12-16
PDF size: 290.79 Kb.

ABSTRACT

Background: Basiliximab is classified as IgG1 monoclonal antibody directed against the interleukin-2 receptor; is a chimeric murine/human antibody indicated as induction therapy in renal transplantation and in combination with other immunosuppressive drugs to prevent acute rejection. Objective: To assess the efficacy of induction therapy with basiliximab per protocol in kidney transplant patients. Methodology: This is an observational, retrospective, descriptive, single-center study, conducted in the period between January 1999 and December 2010. A systematic review of the patient´s records of who received kidney transplants and induction therapy with basiliximab; the primary outcome measures were mortality and rejection rate. Results: Of 496 kidney transplant patients over a period of 12 years, 278 received induction therapy with basiliximab (56%); 129 subjects with daclizumab (26%); four with Thymoglobulin (0.8%), and there were 85 patients without induction (17.2%). People with basiliximab showed 6.8% of acute rejection, chronic rejection 5.3% and 5% mortality. Conclusion: Induction therapy with basiliximab significantly reduces the proportion of patients who experienced acute rejection during the first year, so it is an effective and safe procedure with rejection rates similar to those reported in the literature.

REFERENCES

1. McKeage K, McCormack PL. Basiliximab: a review of its use as induction therapy in renal transplantation. BioDrugs. 2010; 24 (1): 55-76.

2. Tang IY, Meier-Kreische HU, Kaplan B. Immunosuppresive strategies to improve outcomes of kidney transplantation recipients. Semin Nephrol. 2007; 27 (4): 377-392.

3. Sterkers G, Baudouin V, Ansart-Pirenne H et al. Duration of action of chimeric interleukin-2 receptor monoclonal antibody, basiliximab, in pediatric kidney transplantation recipients. Transplant Proc. 2000; 32 (8): 2757-2759.

4. Lebranchu Y, Bridoux F, Büchler M et al. Immunoprophylaxis with basiliximab compared with anithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant. 2002; 2 (1): 48-56.

5. Jorge S, Guerra J, Silva S et al. Induction immunosppresive therapy in renal transplantation: does basiliximab make the difference? Transplant Proc. 2008; 40 (3): 693-696.

6. Sheashaa HA, Bakr MA, Ismail AM et al. Long-term evaluation of basiliximab induction therapy in the live donor kidney transplantation: a five-year prospective randomized study. Am J Nephrol. 2005; 25 (3): 221-225.

7. Keown P, Balshaw R, Khorasheh S et al. Meta-analysis of basiliximab for immunoprophylaxis in renal transplantation. BioDrugs. 2003; 17 (4): 271-279.

8. Webster AC, Playford EG, Higgins G et al. Interleukin-2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation. 2004; 77 (2): 166-176.